GHK-Cusafety profile & UK regulatory status

This page summarises the published safety profile, contraindications, formulation interactions, and UK regulatory status for GHK-Cu as reported in the pre-clinical research literature. It is a research-orientation reference and not a clinical safety assessment. GHK-Cu is not licensed as a medicine in the United Kingdom and may not be supplied or administered to humans outside an authorised clinical-trial framework.

Safety profile

Topical GHK-Cu has an extensive safety record as a cosmetic ingredient at concentrations typically ranging from 0.05% to 0.5% weight-per-volume in marketed products. At these concentrations, adverse effects are rare; mild transient erythema and occasional contact sensitisation have been reported in patch-test literature, but serious cutaneous adverse events have not been documented. The characteristic blue colour of copper-tripeptide preparations is a helpful visual quality control marker — degraded or oxidised preparations lose their blue colour. In-vitro and small-animal studies of injectable preparations have not identified acute organ toxicity. The critical concern with copper-containing compounds is the potential for copper overload at supraphysiological concentrations — free ionic copper is pro-oxidant and cytotoxic, particularly when generated in the presence of hydrogen peroxide through Fenton-type chemistry. GHK-Cu at physiologically relevant concentrations does not appear to liberate significant free copper because the tripeptide binds copper with high affinity (~10^-16 M dissociation constant) and buffers ionic copper effectively. However, at high doses, with compromised endogenous copper metabolism (e.g. Wilson's disease), or with concurrent zinc deficiency (which impairs metallothionein-buffering of copper), caution is warranted. Contraindications and precautions include: Wilson's disease and other genetic copper-handling disorders; hepatic impairment where copper elimination may be compromised; concurrent copper supplementation from other sources; and IUD contexts where systemic copper effects have theoretical concerns. Pregnancy and lactation safety data are limited and cosmetic use has been the majority experience — systemic research administration should be avoided. Systemic long-term safety data for parenteral or high-dose GHK-Cu are absent — this is the principal knowledge gap for research and clinical translation of the compound. Researchers planning systemic animal studies should pilot-test doses and monitor hepatic copper accumulation via ceruloplasmin and hepatic-copper measurements. For topical laboratory preparations, standard cosmetic-grade safety testing (repeat-insult patch testing, phototoxicity, ocular-irritation for eye-adjacent applications) is relevant to any formulation intended for prolonged skin contact. Sterility and endotoxin testing apply to any injectable research preparation.

UK regulatory status

GHK-Cu (listed under the INCI name Copper Tripeptide-1) is a legally permitted cosmetic ingredient in the United Kingdom, regulated under the UK Cosmetic Products Regulation (Retained Regulation (EC) 1223/2009 as amended). There is no specific restriction or concentration limit on GHK-Cu in cosmetic formulations, provided the product overall meets the general safety obligation and is manufactured to appropriate standards. As a research peptide for injectable or systemic experimental use, GHK-Cu is not licensed as a medicine by the MHRA. No marketing authorisation, investigational product certificate, or orphan designation is held by any sponsor in the UK for therapeutic GHK-Cu. Researchers conducting animal studies with GHK-Cu in the UK should hold appropriate Home Office project licences under the Animals (Scientific Procedures) Act 1986 (ASPA). GHK-Cu is not currently listed on the WADA Prohibited List, and its primary applications (topical cosmetic, dermatological research) do not intersect with anti-doping concerns. However, any systemic research administration in an athlete context should be reviewed against the current Prohibited List for substances not specifically named but potentially covered by class-based prohibitions.

What 'research-use-only' means in the UK

The UK regulatory position on research peptides sits across four distinct frameworks: MHRA medicines licensing, the Human Medicines Regulations 2012, the Misuse of Drugs Act 1971, and the WADA Prohibited List. GHK-Cu is not an MHRA-licensed medicine; possession for bona fide in-vitro or ex-vivo laboratory research is generally lawful, while supply or administration to humans engages the Human Medicines Regulations and is generally an offence. For animal-research use, additional permissions are required under the Animals (Scientific Procedures) Act 1986 (ASPA).

For the comprehensive UK regulatory reference covering all four frameworks, see the UK research peptide regulation 2026 reference.

Practical safety considerations for research

Sterility and endotoxin content of research-grade preparations remain the dominant practical safety variables for any injectable in-vivo work, regardless of the intrinsic safety profile of the active peptide. Batch-to-batch verification of HPLC purity and identity (by mass spectrometry where possible) and endotoxin testing by limulus amebocyte lysate (LAL) assay or recombinant Factor C (rFC) assay are standard due-diligence expectations. For research with vertebrate animals in the UK, ASPA project and personal licences are mandatory and the work must pass a local Animal Welfare and Ethical Review Body assessment.

For full GHK-Cu research context including mechanism, study citations, and references, see the main GHK-Cu research profile. For dosing and pharmacokinetic context, see the dosing reference and half-life reference pages.